These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 29520760)
41. Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Driver JP; Scheuplein F; Chen YG; Grier AE; Wilson SB; Serreze DV Diabetes; 2010 Feb; 59(2):423-32. PubMed ID: 19903740 [TBL] [Abstract][Full Text] [Related]
42. Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain. Kim TC; Park HJ; Lee SW; Park YH; Van Kaer L; Hong S Inflamm Res; 2024 Sep; 73(9):1511-1527. PubMed ID: 39028491 [TBL] [Abstract][Full Text] [Related]
43. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Park O; Jeong WI; Wang L; Wang H; Lian ZX; Gershwin ME; Gao B Hepatology; 2009 May; 49(5):1683-94. PubMed ID: 19205035 [TBL] [Abstract][Full Text] [Related]
44. Reconstitution models to evaluate natural killer T cell function in tumor control. Gebremeskel S; Slauenwhite D; Johnston B Immunol Cell Biol; 2016 Jan; 94(1):90-100. PubMed ID: 26095148 [TBL] [Abstract][Full Text] [Related]
45. In vivo and in vitro analyses of α-galactosylceramide uptake by conventional dendritic cell subsets using its fluorescence-labeled derivative. Ushida M; Iyoda T; Kanamori M; Watarai H; Takahara K; Inaba K Immunol Lett; 2015 Dec; 168(2):300-5. PubMed ID: 26481266 [TBL] [Abstract][Full Text] [Related]
46. Role of marginal zone B lymphocytes in invariant NKT cell activation. Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762 [TBL] [Abstract][Full Text] [Related]
47. Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties. Choi J; Rudak PT; Lesage S; Haeryfar SMM J Immunol; 2019 Oct; 203(7):1808-1819. PubMed ID: 31462506 [TBL] [Abstract][Full Text] [Related]
48. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Durgan K; Ali M; Warner P; Latchman YE Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487 [TBL] [Abstract][Full Text] [Related]
49. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881 [TBL] [Abstract][Full Text] [Related]
50. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells. Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291 [TBL] [Abstract][Full Text] [Related]
51. Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide. Meng M; Chen S; Gao X; Liu H; Zhao H; Zhang J; Zhang J; Chen D Iran J Allergy Asthma Immunol; 2020 Feb; 19(1):35-44. PubMed ID: 32245319 [TBL] [Abstract][Full Text] [Related]
52. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer. Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE Cancer Immun; 2013; 13():9. PubMed ID: 23885215 [TBL] [Abstract][Full Text] [Related]
53. Impact of Th1/Th2 cytokine polarity induced by invariant NKT cells on the incidence of pregnancy loss in mice. Hoya M; Nagamatsu T; Fujii T; Schust DJ; Oda H; Akiba N; Iriyama T; Kawana K; Osuga Y; Fujii T Am J Reprod Immunol; 2018 Mar; 79(3):. PubMed ID: 29363849 [TBL] [Abstract][Full Text] [Related]
54. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. Hung JT; Huang JR; Yu AL J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781 [TBL] [Abstract][Full Text] [Related]
55. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972 [TBL] [Abstract][Full Text] [Related]
56. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15. Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686 [TBL] [Abstract][Full Text] [Related]
57. Infiltration of invariant natural killer T cells occur and accelerate brain infarction in permanent ischemic stroke in mice. Wang ZK; Xue L; Wang T; Wang XJ; Su ZQ Neurosci Lett; 2016 Oct; 633():62-68. PubMed ID: 27637387 [TBL] [Abstract][Full Text] [Related]
58. Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. Paget C; Ivanov S; Fontaine J; Blanc F; Pichavant M; Renneson J; Bialecki E; Pothlichet J; Vendeville C; Barba-Spaeth G; Huerre MR; Faveeuw C; Si-Tahar M; Trottein F J Immunol; 2011 May; 186(10):5590-602. PubMed ID: 21490153 [TBL] [Abstract][Full Text] [Related]
59. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells. Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226 [TBL] [Abstract][Full Text] [Related]
60. Differential dendritic cell-mediated activation and functions of invariant NKT-cell subsets in oral cancer. Singh AK; Gaur P; Shukla NK; Das SN Oral Dis; 2015 Jan; 21(1):e105-13. PubMed ID: 24654917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]